安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Ruxolitinib - Wikipedia
In the European Union, ruxolitinib cream is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age
- Ruxolitinib: Uses, Dosage, Side Effects Warnings - Drugs. com
Ruxolitinib (oral) is used to treat certain types of myelofibrosis (MF), polycythemia vera (PV), and graft-versus-host disease The brand name is Jakafi, and it is an oral tablet taken daily Topical ruxolitinib is used for atopic dermatitis (eczema) and nonsegmental vitiligo
- Polycythemia Vera, Myelofibrosis, Acute Chronic Graft-Versus-Host . . .
JAKAFI or JAKAFI XR is a prescription medication used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough
- Ruxolitinib (oral route) - Side effects dosage - Mayo Clinic
Ruxolitinib is used to treat intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis
- JAKAFI (Ruxolitinib) Label - Food and Drug Administration
Ruxolitinib is the predominant entity in humans representing approximately 60% of the drug-related material in circulation Two major and active metabolites were identified in plasma of healthy
- Jakafi (Ruxolitinib): Uses, Side Effects, Interactions . . . - WebMD
Jakafi (ruxolitinib) is commonly used to treat certain types of blood cancers, including myelofibrosis (MF) and polycythemia vera It is also used to treat graft versus host disease (GVHD)
- Ruxolitinib: MedlinePlus Drug Information
Ruxolitinib is in a class of medications called kinase inhibitors It works to treat myelofibrosis and PV by blocking the signals that cause cancer cells to multiply
- Ruxolitinib: Side Effects, Uses, Dosage, Interactions, Warnings - RxList
What Is Ruxolitinib and How Does It Work? Ruxolitinib is a prescription medicine used to treat adults with certain bone marrow disorders, including myelofibrosis and polycythemia vera
|
|
|